Do cancer patients overestimate drug benefits? a trial puts communication to the test.

NCT ID NCT07731425

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This study asks whether adding overall survival data to standard progression-free survival information helps current or former cancer patients more accurately judge a new drug's survival benefit. Around 3,000 U.S. adults with a past or present cancer diagnosis will read about a hypothetical cancer drug and answer questions about its effectiveness. The goal is to see if clearer communication reduces unrealistic expectations.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to
If successful, this could improve how doctors communicate drug benefits, helping patients make more informed treatment decisions.
What could go wrong
This is a survey-based study, not a treatment trial. It measures expectations, not actual outcomes, and results may not change real-world practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Harvard Medical School and Harvard Pilgrim Health Care Institute

    Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.